How is muscle atrophy evaluated or diagnosed?

Muscle atrophy—the progressive loss of muscle mass and strength—requires a systematic diagnostic evaluation to identify the underlying cause. Initial assessment begins with a detailed history, including onset (acute vs. chronic), progression pattern (symmetric vs. asymmetric), associated symptoms (e.g., weakness, cramps, fasciculations, sensory changes, fatigue, or weight loss), and relevant medical, family, medication, and exposure history.

Physical examination focuses on documenting distribution and severity of atrophy (e.g., distal vs. proximal, limb-specific, or cranial nerve involvement), assessing muscle strength using the Medical Research Council (MRC) scale, evaluating deep tendon reflexes, testing sensation, and observing for signs such as fasciculations, myotonia, or contractures.

First-line investigations typically include serum creatine kinase (CK) to screen for myopathic injury, electrolytes (especially potassium, calcium, and magnesium), thyroid-stimulating hormone (TSH), vitamin D, and complete blood count. Depending on clinical suspicion, additional blood tests may include inflammatory markers (ESR, CRP), autoantibodies (e.g., anti-Jo-1, anti-SRP), HIV serology, paraneoplastic panels, or genetic testing for inherited neuromuscular disorders.

Electrodiagnostic studies—including nerve conduction studies (NCS) and needle electromyography (EMG)—are critical for differentiating neurogenic atrophy (e.g., from motor neuron disease, peripheral neuropathy, or radiculopathy) from primary myopathic processes. EMG findings such as increased insertional activity, fibrillation potentials, positive sharp waves, and reduced recruitment favor neurogenic causes; whereas short-duration, low-amplitude motor unit potentials suggest myopathy.

Muscle imaging—particularly MRI of affected regions—can reveal patterns of fatty infiltration, edema, or selective involvement that help localize pathology and guide biopsy site selection. When indicated, muscle biopsy provides histopathological, histochemical, and molecular insights into inflammatory, dystrophic, metabolic, or mitochondrial myopathies.

In select cases, advanced testing may be warranted: spinal MRI for suspected compressive myelopathy or radicular disease; whole-body PET-CT if malignancy-associated paraneoplastic syndrome is suspected; or genetic sequencing (e.g., whole-exome or targeted panels) for hereditary motor-sensory neuropathies, muscular dystrophies, or spinal muscular atrophy.

A multidisciplinary approach—often involving neurology, physical medicine and rehabilitation, genetics, and specialized neuromuscular centers—is essential to ensure accurate diagnosis, timely intervention, and appropriate supportive care.